AZD5069 Neutrophil Function Study
Study identifier:D3550C00017
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double-blind, Placebo-Controlled, Two-way Cross-over, Single Centre Study in Healthy Subjects to Assess the Effect of Oral Dosing of AZD5069 on Neutrophil Number and Function in Peripheral Blood and the Ability to Recruit Neutrophils into the Circulation after Exercise and Subcutaneous
Medical condition
Chemokine receptor 2 (CXCR2) antagonist
Phase
Phase 1
Healthy volunteers
Yes
Study drug
100 mg (50 mg x 2) AZD5069, 100 mg Placebo
Sex
All
Actual Enrollment
30
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Dec 2011
Primary Completion Date: 01 Jul 2012
Study Completion Date: 01 Jul 2012
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Aug 2015 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD5069 100 mg capsules (50 mg BD) for 7 days | Drug: 100 mg (50 mg x 2) AZD5069 Twice daily for 7 days |
| Experimental: 2 Placebo twice daily for 7 days | Drug: 100 mg Placebo Twice daily for 7 days |
Contacts
Investigators
Principal Investigator
Tim Mant
Quintiles research Unit
